Implicity02.04.22
Implicity has welcomed two new members to its management team. Cardiac electrophysiology professionals Prof. Niraj Varma, M.D., Ph.D., and Kevin Campbell, M.D., FACC, have been named scientific advisors for the company.
“We’re thrilled to welcome these two impressive experts who bring with them a wealth of knowledge and insights that will no doubt add tremendous value as we expand our footprint globally and continue to lead innovation in remote monitoring and artificial intelligence. Based on their field-based feedback, our development and R&D teams will be able to improve our AI-based technology and our data management solutions to provide the best patient-care options to electrophysiologists and device nurses worldwide,” said Dr. Arnaud Rosier, CEO and co-founder of Implicity.
The two clinicians will help guide the development of new products, capabilities, and services as Implicity deploys its platform globally. They will support Implicity’s mission to democratize cardiac remote monitoring and equip U.S. facilities with cutting-edge innovation in remote monitoring for a more effective patient-care.
Varma is a professor of Medicine and consultant electrophysiologist at the Cleveland Clinic who pioneered the use of remote monitoring technology of implantable devices. He led landmark clinical trials and co-chaired recommendations for clinical use. Varma received his doctorate from Oxford University and trained in cardiac clinical electrophysiology at Harvard Medical School. A dedicated researcher, he has received grants from the American Heart Association (AHA), a National Research Service Award, and industry funding for studies of innovative technology. Varma is a reviewer for several leading medical journals, including New England Journal of Medicine, Lancet, Circulation, Journal of the American College of Cardiology, Heart Rhythm, PACE, and Journal of Cardiovascular Electrophysiology.
Campbell is an internationally recognized cardiologist who specializes in diagnosing and treating heart rhythm disorders. He’s also the former CEO of PaceMate, a cloud-based software platform for remote cardiac care management. Campbell completed his cardiology training at Duke University Medical Center and has collaborated with some of the world’s most distinguished researchers throughout his career.
The author of two books and contributor to U.S. News & World Report, Fox News Channel, and other nationally recognized media outlets, Campbell currently practices cardiology and cardiac electrophysiology in Melbourne, Fla., with Health First Medical Group. He is also a Fellow of the American College of Cardiology (ACC) and has held numerous leadership roles with the Heart Rhythm Society (HRS).
Implicity is a digital medtech firm providing a remote monitoring and research platform used by independent diagnostic testing facilities and cardiac electrophysiology centers to deliver care for their patients with connected cardiac implantable electronic devices. On this platform, Implicity aggregates, normalizes, and standardizes data from any implantable cardiac devices across all manufacturers. Implicity also carries out R&D on AI-based algorithms aiming at preventive medicine and improving patient care. Implicity has been the first private company authorized to access the Health Data Hub, one of world's largest databases of patients with heart disease, supporting the development of its AI solutions. Implicity covers more than 45,000 patients in over 70 medical facilities across Europe and the United States.
“We’re thrilled to welcome these two impressive experts who bring with them a wealth of knowledge and insights that will no doubt add tremendous value as we expand our footprint globally and continue to lead innovation in remote monitoring and artificial intelligence. Based on their field-based feedback, our development and R&D teams will be able to improve our AI-based technology and our data management solutions to provide the best patient-care options to electrophysiologists and device nurses worldwide,” said Dr. Arnaud Rosier, CEO and co-founder of Implicity.
The two clinicians will help guide the development of new products, capabilities, and services as Implicity deploys its platform globally. They will support Implicity’s mission to democratize cardiac remote monitoring and equip U.S. facilities with cutting-edge innovation in remote monitoring for a more effective patient-care.
Varma is a professor of Medicine and consultant electrophysiologist at the Cleveland Clinic who pioneered the use of remote monitoring technology of implantable devices. He led landmark clinical trials and co-chaired recommendations for clinical use. Varma received his doctorate from Oxford University and trained in cardiac clinical electrophysiology at Harvard Medical School. A dedicated researcher, he has received grants from the American Heart Association (AHA), a National Research Service Award, and industry funding for studies of innovative technology. Varma is a reviewer for several leading medical journals, including New England Journal of Medicine, Lancet, Circulation, Journal of the American College of Cardiology, Heart Rhythm, PACE, and Journal of Cardiovascular Electrophysiology.
Campbell is an internationally recognized cardiologist who specializes in diagnosing and treating heart rhythm disorders. He’s also the former CEO of PaceMate, a cloud-based software platform for remote cardiac care management. Campbell completed his cardiology training at Duke University Medical Center and has collaborated with some of the world’s most distinguished researchers throughout his career.
The author of two books and contributor to U.S. News & World Report, Fox News Channel, and other nationally recognized media outlets, Campbell currently practices cardiology and cardiac electrophysiology in Melbourne, Fla., with Health First Medical Group. He is also a Fellow of the American College of Cardiology (ACC) and has held numerous leadership roles with the Heart Rhythm Society (HRS).
Implicity is a digital medtech firm providing a remote monitoring and research platform used by independent diagnostic testing facilities and cardiac electrophysiology centers to deliver care for their patients with connected cardiac implantable electronic devices. On this platform, Implicity aggregates, normalizes, and standardizes data from any implantable cardiac devices across all manufacturers. Implicity also carries out R&D on AI-based algorithms aiming at preventive medicine and improving patient care. Implicity has been the first private company authorized to access the Health Data Hub, one of world's largest databases of patients with heart disease, supporting the development of its AI solutions. Implicity covers more than 45,000 patients in over 70 medical facilities across Europe and the United States.